Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Muscle Toxicity

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Leukemia ◽

10.1038/leu.2016.231 ◽

2016 ◽

Vol 31 (3) ◽

pp. 585-592 ◽

Cited By ~ 21

Author(s):

Z Chen ◽

C Shao ◽

W Wang ◽

Z Zuo ◽

X Mou ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Blast Phase ◽

Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity

Haematologica ◽

10.3324/haematol.2020.247767 ◽

2020 ◽

pp. haematol.2020.247767

Author(s):

Lando Janssen ◽

Nicole M.A. Blijlevens ◽

Meggie M.C.M. Drissen ◽

Esmée A. Bakker ◽

Malou A.H. Nuijten ◽

...

Keyword(s):

Physical Activity ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

The Relationship

Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

Value in Health ◽

10.1016/j.jval.2020.10.007 ◽

2020 ◽

Vol 23 (12) ◽

pp. 1671-1672

Keyword(s):

Cost Effectiveness ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

First Line ◽

Therapy Initiation ◽

Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy

Current Medical Science ◽

10.1007/s11596-019-2021-7 ◽

2019 ◽

Vol 39 (2) ◽

pp. 211-216 ◽

Cited By ~ 1

Author(s):

Na Shen ◽

Yong You ◽

Zhao-dong Zhong ◽

Li Meng ◽

Jian-feng Zhou ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

Haematologica ◽

10.3324/haematol.2009.015271 ◽

2009 ◽

Vol 95 (6) ◽

pp. 900-907 ◽

Cited By ~ 39

Author(s):

T. Lenaerts ◽

J. M. Pacheco ◽

A. Traulsen ◽

D. Dingli

Keyword(s):

Stem Cells ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Leukemic Stem Cells ◽

Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

Value in Health ◽

10.1016/j.jval.2020.05.019 ◽

2020 ◽

Vol 23 (10) ◽

pp. 1292-1299 ◽

Cited By ~ 1

Author(s):

Joehl T. Nguyen ◽

Ashley L. Cole ◽

Ashley A. Leech ◽

William A. Wood ◽

Stacie B. Dusetzina

Keyword(s):

Cost Effectiveness ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

First Line ◽

Therapy Initiation ◽

Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1842397 ◽

2020 ◽

pp. 1-9

Author(s):

Dayu Shi ◽

Zongru Li ◽

Yongjie Li ◽

Qian Jiang

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Anxiety And Depression ◽

Depression Symptoms ◽

Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

The Oncologist ◽

10.1634/theoncologist.2019-0109 ◽

2019 ◽

Vol 24 (11) ◽

Cited By ~ 3

Author(s):

Xuelin Dou ◽

Yazhen Qin ◽

Xiaojun Huang ◽

Qian Jiang

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Female Patients ◽

Planned Pregnancy

The incidence of atypical patterns ofBCR-ABL1rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML)

Blood Research ◽

10.5045/br.2018.53.2.152 ◽

2018 ◽

Vol 53 (2) ◽

pp. 152

Author(s):

Željka Tkalčić Švabek ◽

Marina Josipović ◽

Ivana Horvat ◽

Renata Zadro ◽

Sanja Davidović-Mrsić

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Cytogenetic Response ◽

Inhibitor Therapy ◽

Newly Diagnosed ◽

Molecular Cytogenetic ◽

Healthcare Utilization and Costs Associated With Multiple Switching of Tyrosine Kinase Inhibitor therapy In Patients With Chronic Myeloid Leukemia

Value in Health ◽

10.1016/j.jval.2015.03.1155 ◽

2015 ◽

Vol 18 (3) ◽

pp. A199

Author(s):

P. Kropf ◽

G. Barnes ◽

B. Tang ◽

A. Pathak ◽

J. Issa

Keyword(s):

Tyrosine Kinase ◽

Healthcare Utilization ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Multiple Switching